Get 20% Free Customization In This Report

Buy this report from - $3456

Acute Coronary Syndrome (ACS) Market by Type (Unstable Angina (UA), ST-elevation Myocardial Infarction (STEMI) and Non-ST-elevation Myocardial Infarction (NSTEMI)), and by Drug (Antihypertensive Drug, Antithrombotic Drug and Statins Drug) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Pharmaceuticals	LI_184038	Pages: NA	Jul 2018 \| 603 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Acute coronary syndrome refers to the clinical condition in which there is a decrease in the blood flow through the coronary arteries due to improper functioning of the heart muscles or any damage to the heart muscles. The symptoms may include chest pain, pain or discomfort in one or both arms, shortness of breath, nausea, sweating, and others. Blood tests or ECG can be done to diagnose ACS. Medicines and angioplasty are used to treat ACS.

Increase in geriatric population and rise in the incidence of cardiac disorders are the major factors that drive the market growth. However, stringent government regulations for the approval of drugs are expected to restrain the market growth. Improvement in healthcare facilities in emerging regions such as Asia-Pacific and LAMEA are expected to provide new growth opportunities for the market during the analysis period.

The acute coronary syndrome market is segmented on the basis of type, drug, and region. Based on type the market is segmented into Unstable Angina (UA), ST-elevation Myocardial Infarction (STEMI), and Non-ST-elevation Myocardial Infarction (NSTEMI). Based on drug the market is bifurcated into antihypertensive drug, antithrombotic drug, and statins drug. By region, it has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

The study provides an in-depth analysis of the global acute coronary syndrome market, with current trends and future estimations to elucidate investment pockets.
Comprehensive analysis of factors that drive and restrict the growth of the market has been provided.
The report offers a quantitative analysis to assist stakeholders to capitalize on prevailing market opportunities.
Extensive analysis of different segments determines various products available in the market.
Key players have been profiled and their strategies thoroughly analyzed to predict the competitive market outlook.

Acute Coronary Syndrome (ACS) Market Key Segments:

By Type

Vial Unstable Angina (UA)
ST-elevation Myocardial Infarction (STEMI)
Non-ST-elevation Myocardial Infarction (NSTEMI)

By Drug

Antihypertensive Drug
Antithrombotic Drug
Statins Drug

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
LAMEA
- Latin America
- The Middle East
- Africa

List of players profiled in the report

Pfizer Inc.
Sanofi S.A.
GlaxoSmithKline Plc
Merck & Co.
AstraZeneca
Baxter International Inc.
Beijing Minhai Biotechnology
Serum Institute of India
Biogen Inc.
Eli Lilly and Company

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 ACUTE CORONARY SYNDROME MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. VIAL UNSTABLE ANGINA

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. ST-ELEVATION MYOCARDIAL INFARCTION

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. NON-ST-ELEVATION MYOCARDIAL INFARCTION

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

Chapter: 5 ACUTE CORONARY SYNDROME MARKET, BY DRUG

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ANTIHYPERTENSIVE DRUG

5.2.1. Market size and forecast

5.3. ANTITHROMBOTIC DRUG

5.3.1. Market size and forecast

5.4. STATINS DRUG

5.4.1. Market size and forecast

Chapter: 6 ACUTE CORONARY SYNDROME MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Acute Coronary Syndrome Market by Type
6.2.5. North America Acute Coronary Syndrome Market by Drug

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Acute Coronary Syndrome Market by Type
6.3.5. Europe Acute Coronary Syndrome Market by Drug

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. India market size and forecast
6.4.3.4. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Acute Coronary Syndrome Market by Type
6.4.5. Asia-Pacific Acute Coronary Syndrome Market by Drug

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Latin America market size and forecast
6.5.3.2. Middle East market size and forecast
6.5.3.3. Africa market size and forecast

6.5.4. LAMEA Acute Coronary Syndrome Market by Type
6.5.5. LAMEA Acute Coronary Syndrome Market by Drug

Chapter: 7 COMPANY PROFILES

7.1. PFIZER INC.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. SANOFI S.A.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. GLAXOSMITHKLINE PLC

7.3.1. Operating business segments
7.3.2. Business performance

7.4. MERCK & CO.

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. ASTRAZENECA

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. BAXTER INTERNATIONAL INC.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. BEIJING MINHAI BIOTECHNOLOGY

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. SERUM INSTITUTE OF INDIA

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. BIOGEN INC.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. ELI LILLY AND COMPANY

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty